Molecular heterogeneity of triple-negative breast cancer and its clinical implications

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase

(2011) Tingting Sun et al.   CELL

p53 Status Identifies Two Subgroups of Triple-negative Breast Cancers with Distinct Biological Features

(2011) E. Biganzoli et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Unmeasured Costs of a Child's Death: Perceived Financial Burden, Work Disruptions, and Economic Coping Strategies Used by American and Australian Families Who Lost Children to Cancer

(2011) Veronica Dussel et al.   JOURNAL OF CLINICAL ONCOLOGY

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

(2011) Joyce O'Shaughnessy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of HER2-overexpressing breast cancer

(2010) J. Baselga   ANNALS OF ONCOLOGY

Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up

(2010) Lisa Rydén et al.   BREAST CANCER RESEARCH AND TREATMENT

Triple-Negative Breast Cancer

(2010) Steven J. Isakoff   CANCER JOURNAL

LYN Is a Mediator of Epithelial-Mesenchymal Transition and a Target of Dasatinib in Breast Cancer

(2010) Y.-L. Choi et al.   CANCER RESEARCH

The Met receptor tyrosine kinase and basal breast cancer

(2010) Marisa G. Ponzo et al.   CELL CYCLE

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

(2010) M. Graeser et al.   CLINICAL CANCER RESEARCH

Beyond triple-negative breast cancer: the need to define new subtypes

(2010) Anastasia Constantinidou et al.   Expert Review of Anticancer Therapy

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies

(2010) Daniel J. Toft et al.   MOLECULAR ENDOCRINOLOGY

Genome remodelling in a basal-like breast cancer metastasis and xenograft

(2010) Li Ding et al.   NATURE

Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer

(2009) G. Frasci et al.   ANNALS OF ONCOLOGY

Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer

(2009) B. K. Linderholm et al.   ANNALS OF ONCOLOGY

Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition

(2009) O. K. Mirzoeva et al.   CANCER RESEARCH

Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics

(2009) B. T. Hennessy et al.   CANCER RESEARCH

Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes

(2009) E. A. Rakha et al.   CLINICAL CANCER RESEARCH

Triple negative breast cancer: current understanding of biology and treatment options

(2009) Soonmo Peter Kang et al.   CURRENT OPINION IN OBSTETRICS & GYNECOLOGY

PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality

(2009) Elena López-Knowles et al.   INTERNATIONAL JOURNAL OF CANCER

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation

(2009) G. Solinas et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Mixed micropapillary–ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components

(2009) Caterina Marchiò et al.   JOURNAL OF PATHOLOGY

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes

(2008) F.-C. Bidard et al.   ANNALS OF ONCOLOGY

Platinum-based chemotherapy in triple-negative breast cancer

(2008) B. Sirohi et al.   ANNALS OF ONCOLOGY

Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker

(2008) Bhumsuk Keam et al.   BMC CANCER

Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis

(2008) Britta Weigelt et al.   BREAST CANCER RESEARCH AND TREATMENT

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

(2008) T. Byrski et al.   BREAST CANCER RESEARCH AND TREATMENT

TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype

(2008) Monzur Rahman et al.   BREAST CANCER RESEARCH AND TREATMENT

Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity

(2008) Giuseppe Viale et al.   BREAST CANCER RESEARCH AND TREATMENT

Triple-Negative Breast Cancer and Obesity in a Rural Appalachian Population

(2008) L. Vona-Davis et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Met and c-Src Cooperate to Compensate for Loss of Epidermal Growth Factor Receptor Kinase Activity in Breast Cancer Cells

(2008) K. L. Mueller et al.   CANCER RESEARCH

Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype

(2008) D. Sarrio et al.   CANCER RESEARCH

Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer

(2008) Alfonso Sánchez-Muñoz et al.   Clinical & Translational Oncology

RiBBON 1 and RiBBON 2: Phase III Trials of Bevacizumab with Standard Chemotherapy for Metastatic Breast Cancer

(2008) Joyce A. O'Shaughnessy et al.   Clinical Breast Cancer

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

(2008) C. Desmedt et al.   CLINICAL CANCER RESEARCH

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

(2008) M. C.U. Cheang et al.   CLINICAL CANCER RESEARCH

Expression of BRCA1 protein in breast cancer and its prognostic significance

(2008) Emad A. Rakha et al.   HUMAN PATHOLOGY

A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair

(2008) Alan Ashworth   JOURNAL OF CLINICAL ONCOLOGY

Protein Profiling of Human Breast Tumor Cells Identifies Novel Biomarkers Associated with Molecular Subtypes

(2008) Anthony Gonçalves et al.   MOLECULAR & CELLULAR PROTEOMICS

The basal-like breast carcinoma phenotype is regulated bySLUGgene expression

(2007) G Storci et al.   JOURNAL OF PATHOLOGY